Hemochromatosis: Diagnosis and management

Gastroenterology

Volumn 120, Issue 3, 2001, Pages 718-725

  Bacon, Bruce R ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD ANALYSIS; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; GENETIC ANALYSIS; HEMOCHROMATOSIS; HUMAN; MASS SCREENING; PATHOGENESIS; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW;

EID: 0035116099     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.21913     Document Type: Article

References (59)

1. Hemochromatosis and the iron overload syndromes
2. Molecular medicine and hemochromatosis: At the crossroads
3. Haemochromatosis in the new millennium
4. Idiopathic hemochromatosis. Demonstration of recessive transmission and early detection by family HLA typing
5. A novel MHC class 1-like gene is mutated in patients with hereditary haemochromatosis
6. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene
7. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22
8. EASL International Consensus Conference on Haemochromatosis
9. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor
10. Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor
11. Two novel missense mutations of the HFE gene (1105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands
12. Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis
13. HFE gene knockout produces mouse model of hereditary hemochromatosis
14. The C282Y mutation causing hereditary hemochromatosis does not produce a null allele
15. Experimental hemochromatosis due to MHC class I HFE deficiency: Immune status and iron metabolism
16. Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract
17. Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum
18. Iron overload: Molecular clues to its cause
19. Disorders of iron metabolism
20. Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: Increased duodenal expression of the iron transporter DMT1
21. Duodenal metaltransporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis
22. Hereditary hemochromatosis: Diagnosis in the 1990's
23. A population-based study of the clinical expression of the hemochromatosis gene
24. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic
25. Measurement of iron status in patients with chronic hepatitis
26. Nonalcoholic steatohepatitis: An expanded clinical entity
27. Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis
28. HFE geno-type in patients with hemochromatosis and other liver diseases
29. Histological evaluation of iron in liver biopsies: Relationship to HFE mutations
30. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis
31. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis
32. Hereditary hemochromatosis
33. Implications of genotyping of spouses to limit investigation of children in genetic hemochromatosis
34. The haemochromatosis gene: A co-factor for chronic liver diseases?
35. Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis
36. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease
37. Response to interferon α therapy is influenced by the iron content of the liver
38. Hepatic iron concentration as a predictor of response to interferon α therapy in chronic hepatitis C
39. Iron stores, response to α-interferon therapy, and effects of iron depletion in chronic hepatitis C
40. Liver iron influences the response to interferon α therapy in chronic hepatitis C
41. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α-interferon in patients with chronic hepatitis C
42. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial
43. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial
44. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C
45. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C
46. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection?
47. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis
48. Hepatic iron overload in patients with chronic viral hepatitis: Role of HFE gene mutations
49. Liver iron accumulation in patients with chronic active hepatitis C: Prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions
50. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C
51. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
52. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
53. Hepatic iron and nonalcoholic fatty liver disease
54. Porphyria cutanea tarda
55. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda
56. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients
57. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America
58. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda
59. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda